🇺🇸 FDA
Pipeline program

eRapa (encapsulated rapamycin)

MTX230-301

Phase 3 small_molecule active

Quick answer

eRapa (encapsulated rapamycin) for Familial Adenomatous Polyposis (FAP) is a Phase 3 program (small_molecule) at Biodexa Pharmaceuticals Plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Biodexa Pharmaceuticals Plc
Indication
Familial Adenomatous Polyposis (FAP)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials